secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001087294-26-000046
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M
--------------------------------------------------------------------------------

- Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.
- Q1 net revenue $9.1M (+5% ex-$3M prior-year milestone); net loss $3.3M; adjusted loss $0.13/share.
- FDA granted Fast Track Designation for ifetroban in Duchenne Muscular Dystrophy; Phase II study showed breakthrough results.
- Ended quarter with $11M cash, $5.2M drawn on credit facility, total assets $71M, equity $21.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/0001087294-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/cpix-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer